Ana Benzaquén

Dec 10, 2024 | nature.com | Valentín Gutiérrez |Marta González Vicent |Ana Benzaquén |Isabel Garcia |Isabel García |Pedro Asensi Cantó | +10 more

AbstractRuxolitinib has been approved for the treatment of adults and pediatric patients ≥12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD.